🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,063 results for “BRIGHT MINDS BIOSCIENCES INC.” Clear

  1. Selegiline

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  2. Selegiline Transdermal Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  3. Selegiline hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  4. Semaglutide

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule active

    1 trial

  5. Semaglutide Pen Injector

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  6. Senicapoc

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  7. Sertraline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  8. Sertraline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule terminated

    1 trial

  9. Sildenafil 50 mg Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Erectile Dysfunction

    phase 2 small molecule completed

    1 trial

  10. Smoking research cigarettes with e-cigarette

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Addiction

    phase 2 small molecule completed

    1 trial

  11. Sofosbuvir

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  12. Standard Cognitive Behavioral Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  13. Standard Treatment As Usual (TAU)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  14. Standard drug counseling

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 2 other completed

    1 trial

  15. Standard intervention (counseling + self-help written materials)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use

    phase 2 other completed

    1 trial

  16. Standard of Care with Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Withdrawal (Disorder)

    phase 2 small molecule active

    1 trial

  17. Standard of care and PrEP Choice at Enrollment

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other active

    1 trial

  18. Study 3: Chronic care management

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking, Tobacco

    phase 2 other completed

    1 trial

  19. Suboxone Remote Observed Dosing

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 other completed

    1 trial

  20. Sugammadex Injection 2mg/kg

    BRIGHT MINDS BIOSCIENCES INC.

    Anesthesia, General

    phase 2 small molecule completed

    1 trial

  21. THC

    BRIGHT MINDS BIOSCIENCES INC.

    THC

    phase 2 small molecule active

    1 trial

  22. TMC207

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  23. TMC207 (J)

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  24. TNX-1300 (Injection)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources